-+ 0.00%
-+ 0.00%
-+ 0.00%

The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

Barchart·08/13/2026 13:31:00
Listen to the news

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings’ (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while NeOnc produced encouraging data for one cancer drug, it also generated human clinical evidence around a non-invasive intranasal delivery strategy designed to reach the brain without relying on conventional systemic delivery across the blood-brain barrier.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.